International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.

نویسندگان

  • Sefayet Karaca
  • Nujen Colak Bozkurt
  • Tomris Cesuroglu
  • Mehmet Karaca
  • Mehmet Bozkurt
  • Erdal Eskioglu
  • Renato Polimanti
چکیده

AIM To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS We investigated two Turkish warfarin-treated cohorts: patients with no history of hemorrhagic or thromboembolic event and patients with major and life-threatening hemorrhagic events. RESULTS International pharmacogenetic algorithms showed good performances in predicting the therapeutic dose of patients with no history of bleedings, but they did not significantly detect the incorrect warfarin dose of patients with major and life-threatening hemorrhagic events. CONCLUSION Although genetic information can predict the therapeutic warfarin dose, the accuracy of the international pharmacogenetic algorithms is not sufficient to be used for warfarin screening in Turkish patients.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Hemorrhagic events in patients receiving heparin or enoxaparin in combination with Oral antithrombotics, NSAIDs, and antiplatelet medications: A multi-center case-series study

Background: Hemorrhagic events are amongst the major adverse effects of injectable anticoagulants such as heparin and enoxaparin. This necessitates close monitoring of their use for clinically relevant drug-drug interactions. Aim: To study the rate of hemorrhagic events, the anatomical site, and the severity of the hemorrhage in patients receiving heparin or enoxaparin in combination with clop...

متن کامل

Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials

AIM Adverse drug events lead to increased morbidity, mortality and health care costs. Pharmacogenetic testing that guides drug prescribing has the potential to reduced adverse drug events and increase drug effectiveness. Our aim was to quantify the clinical effectiveness of genotype-guided prescribing. METHODS Three electronic databases were searched from January 1980 through December 2013. S...

متن کامل

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.

BACKGROUND CYP2C9 and VKORC1 genotyping has been advocated as a means of improving the accuracy of warfarin dosing. However, the effectiveness of genotyping in improving anticoagulation control and reducing major bleeding has not yet been compellingly demonstrated. Genotyping currently costs $400 to $550. METHODS AND RESULTS We constructed a Markov model to evaluate whether and under what cir...

متن کامل

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

The US Food and Drug Administration has updated the label information for warfarin to encourage the use of genetic information before initiating treatment with the drug. We used decision-tree modeling to simulate the outcomes of CYP2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotype-guided dosing in patients in whom warfarin therapy is to be initiated. The inputs for the model were ...

متن کامل

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

BACKGROUND The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results. METHODS We randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a dosing algorithm that included both clinical variables and...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Pharmacogenomics

دوره 16 10  شماره 

صفحات  -

تاریخ انتشار 2015